



NEONATAL Medication Monograph

PARACETAMOL

This document should be read in conjunction with this [DISCLAIMER](#)

Oral: Unrestricted: Any prescriber may initiate treatment




IV: Restricted: Requires Neonatologist or relevant specialist review within 24 hours of initiation

**⚠ Check Route of Administration, Dose and Indication
Caution in Neonates at risk of hepatotoxicity**

Presentation	Oral Mixture: 250mg/5mL IV: 1g/100mL = 10mg/mL
Description	Non-narcotic analgesic and antipyretic
Indications	<ul style="list-style-type: none"> • Analgesia: For relief of postoperative pain and reduce the use of narcotic analgesics in infants ≥ 28 weeks. • Symptomatic fever • Haemodynamically significant Patent Ductus Arteriosis (PDA): Where indomethacin is contraindicated or 2 courses have failed
Contraindications	Contraindicated where patient has hypersensitivity to paracetamol, severe hepatocellular insufficiency or hepatic failure
Precautions	Risk of haemolysis in patients with G6PD Deficiency with high doses
Dosage	See Page 2
Adverse Reactions	<p>Common: nausea, vomiting, constipation, dizziness, pain at injection site, pruritis, hypothermia</p> <p>Serious: skin rash/urticarial, thrombocytopenia, anaphylactic shock, hepatotoxic with chronic use</p>
Compatible Fluids	Glucose 5%, Sodium Chloride 0.9%

Preparation	IV: Use undiluted Oral: Nil																															
Dosage	<p><u>Analgesia/Antipyretic</u></p> <p>Note: IV and Oral</p> <p>When used for analgesia, an initial loading dose of 20mg/kg/dose may be administered if clinically necessary with the maximum daily dose adhered to as stated below. Give maintenance dose 6 hours post loading dose.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr style="background-color: #4a86e8; color: white;"> <th colspan="4" style="text-align: center;">Intravenous Administration</th> </tr> <tr> <th style="width: 25%;">CGA</th> <th style="width: 25%;">Dose</th> <th style="width: 25%;">Frequency</th> <th style="width: 25%;">Max DAILY Dose</th> </tr> </thead> <tbody> <tr> <td>≥ 32 weeks</td> <td>10mg/ kg/ dose</td> <td>Every 6 hours <i>as necessary</i></td> <td>50mg/ kg/ day</td> </tr> </tbody> </table> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr style="background-color: #e67e22; color: white;"> <th colspan="4" style="text-align: center;">Oral Administration</th> </tr> <tr> <th style="width: 25%;">CGA</th> <th style="width: 25%;">Dose</th> <th style="width: 25%;">Frequency</th> <th style="width: 25%;">Max DAILY Dose</th> </tr> </thead> <tbody> <tr> <td>28 to 32 weeks</td> <td>10mg/ kg/ dose</td> <td>Every 6 hours <i>as necessary</i></td> <td>40mg/ kg/ day</td> </tr> <tr> <td>≥ 33 weeks</td> <td>15mg/ kg/ dose</td> <td>Every 6 hours <i>as necessary</i></td> <td>60mg/ kg/ day</td> </tr> </tbody> </table> <p><u>Hemodynamically Significant Patent Ductus Arteriosus (PDA)</u></p> <p>Oral/IV: 15mg/kg/dose every 6 hours for 5 days. DA to be reviewed 3 days after course completion</p>				Intravenous Administration				CGA	Dose	Frequency	Max DAILY Dose	≥ 32 weeks	10mg/ kg/ dose	Every 6 hours <i>as necessary</i>	50mg/ kg/ day	Oral Administration				CGA	Dose	Frequency	Max DAILY Dose	28 to 32 weeks	10mg/ kg/ dose	Every 6 hours <i>as necessary</i>	40mg/ kg/ day	≥ 33 weeks	15mg/ kg/ dose	Every 6 hours <i>as necessary</i>	60mg/ kg/ day
Intravenous Administration																																
CGA	Dose	Frequency	Max DAILY Dose																													
≥ 32 weeks	10mg/ kg/ dose	Every 6 hours <i>as necessary</i>	50mg/ kg/ day																													
Oral Administration																																
CGA	Dose	Frequency	Max DAILY Dose																													
28 to 32 weeks	10mg/ kg/ dose	Every 6 hours <i>as necessary</i>	40mg/ kg/ day																													
≥ 33 weeks	15mg/ kg/ dose	Every 6 hours <i>as necessary</i>	60mg/ kg/ day																													
Adverse Reactions	<p>Common: nausea, vomiting, constipation, dizziness, pain at injection site, pruritis, hypothermia</p> <p>Serious: skin rash/urticarial, thrombocytopenaemia, anaphylactic shock, hepatotoxic with chronic use</p>																															
Compatible Fluids	Glucose 5%, Sodium Chloride 0.9%																															
Preparation	IV: Use undiluted Oral: Nil																															
Administration	IV: Infuse over 15 minutes Oral: Can be given any time with regards to feeds																															

Monitoring	Monitor for analgesic response Monitor temperature if used for fever
Interactions	Barbiturates, carbamazepine and phenytoin may increase clearance of paracetamol.
Storage	Store at room temperature, below 25°C
Notes	Measure the paracetamol level if toxicity is suspected, routine monitoring not required. Antidote for paracetamol overdose: Acetylcysteine
References	Truven Health Analytics. Paracetamol. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2019 [cited 2019 Sept 18]. Available from: https://neofax.micromedexsolutions.com/ Society of Hospital Pharmacists of Australia. Paracetamol: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2018 [cited 2017 Nov 19]. Available from: http://aidh.hcn.com.au Taketomo CK, Hodding JH, Kraus DM. Pediatric and neonatal dosage handbook. Hudson (OH): Lexi Comp; 2010. Terrin, G., et al. (2016). "Paracetamol for the treatment of patent ductus arteriosus in preterm neonates: a systematic review and meta-analysis." <i>Archives of disease in childhood. Fetal and neonatal edition</i> 101 (2): F127-136. Seymour, R. A., et al. (1984). "A comparative study of the effects of aspirin and paracetamol (acetaminophen) on platelet aggregation and bleeding time." <i>Eur J Clin Pharmacol</i> 26 (5): 567-571. 1Acetaminophen: Paediatric Drug Information [Internet] UpToDate [Online Database] Cited 15/11/2019
Related clinical guidelines	Patent Ductus Arteriosis (PDA)
Related policies	WNHS Policy: High Risk Medication List

Keywords:	Paracetamol, pain, analgesia, PDA		
Publishing:	<input checked="" type="checkbox"/> Intranet	<input checked="" type="checkbox"/> Internet	
Document owner:	Head of Department - Neonatology		
Author / Reviewer:	KEMH & PCH Pharmacy / Neonatology Directorate		
Date first issued:	October 2008	Version:	3.3
Last reviewed:	April 2020	Next review date:	January 2023
Endorsed by:	Neonatal Directorate Management Group	Date:	April 2020
Standards Applicable:	NSQHS Standards: 1  Governance, 4  Medication Safety, 8  Acute Deterioration		
<p>Printed or personally saved electronic copies of this document are considered uncontrolled.</p> <p>Access the current version from the WNHS website.</p> <p>For any enquiries relating to this guideline, please email KEMH.PharmacyAdmin@health.wa.gov.au</p>			

© Department of Health Western Australia 2019